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Introduction
Multiple sclerosis (MS) is the most common disa-
bling neurological disease of young adults.1 Both pri-
mary progressive multiple sclerosis (PPMS) and 
secondary progressive multiple sclerosis (SPMS) dis-
eases are part of the same progressive disease spec-
trum which can be further split into ‘active’ and 
‘not-active’ progressive disease based on the presence 
or absence of inflammatory activity demonstrated 
either clinically or radiologically.2,3 Disability wors-
ening in not-active progressive MS is mainly due to 
chronic demyelination and mitochondrial dysfunc-
tion, both of which result in virtual hypoxia leading to 
axonal degeneration.4–6 Although anti-CD20, mitox-
antrone and interferons have shown some efficacy in 
patients with active progressive disease,7–9 there is 
still no approved disease-modifying therapy (DMT) 
in patients with not-active progressive MS, which 
represents a significant unmet medical need.10
MD1003 is an oral formulation of high-dose pharma-
ceutical-grade biotin (10,000 times the recommended 
daily intake) that recently demonstrated promising 
efficacy in patients with not-active progressive MS.11 
Over 90% of the patients (N = 23) treated for 
2–36 months in an open-label pilot study had some 
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degree of clinical improvement, including Expanded 
Disability Status Scale (EDSS) reductions in 22%.11 
Biotin is a cofactor for four essential carboxylases: 
acetyl-CoA carboxylase (expressed in oligodendro-
cytes) generates malonyl-CoA, the building block for 
fatty acid synthesis, whereas pyruvate carboxylase, 
3-methylcrotonyl-CoA carboxylase and propionyl-
CoA carboxylase (expressed in neurons) produce 
intermediates for the tricarboxylic acid cycle.12 
MD1003 may thus be activating carboxylases to sup-
port myelin repair (by enhancing fatty acid synthesis) 
and protecting against hypoxia-driven axonal degen-
eration (by enhancing energy production in neu-
rons).11,12 Based on this unique mechanism of action 
and previous clinical observations, this study was 
designed to assess whether MD1003 could reverse 
disability progression in patients with not-active pro-
gressive MS.
Methods
Study design
Study MS-SPI was a 12-month randomised, double-
blind, placebo-controlled trial followed by an open-
label 12-month extension phase where all patients 
received MD1003. The study was conducted at 16 
French MS reference centres in accordance with 
Good Clinical Practice. The study was approved by 
an independent ethical committee (Comité de 
Protection des Personnes Est 1, Dijon, France; 
approval number: CPP EST I: 2013/36) and was over-
seen by an independent data monitoring committee.
Participants
Eligible patients were 18–75 years old with PPMS or 
SPMS that fulfilled revised McDonald and Lublin cri-
teria with clinical evidence of spastic paraparesis. 
Patients with clinical or radiological evidence of 
inflammatory activity within the previous year were 
excluded. Eligible patients had a baseline EDSS of 
4.5–7 with evidence of disease progression during the 
previous 2 years (an increase of ⩾1 point if EDSS was 
4.5–5.5 and ⩾0.5 point if EDSS was 6–7). Detailed 
eligibility criteria are provided in the supplementary 
materials. All participants provided written informed 
consent at enrolment.
Intervention
During a 12-month placebo-controlled phase, patients 
were randomised (2:1) to receive MD1003 (biotin 
100 mg) or placebo orally thrice daily, stratified by 
study centre only. This was followed by MD1003 
100 mg thrice daily for all patients for a further 
12 months (extension phase). Treatments were pro-
vided in identical capsules containing the same quan-
tity of tasteless white powder. Patients and 
investigators were masked to study treatment during 
the initial 12 months and remained blinded during the 
extension phase as to which treatment was adminis-
tered during the first phase. As it was unlikely that the 
treating neurologist could differentiate active treat-
ment from placebo, the treating and examining neu-
rologist could be the same individual.
All concomitant medications were allowed through-
out the study, including immune modulators and 
immunosuppressive drugs provided they were intro-
duced at least 3 months before inclusion (⩾1 month 
for fampridine). Intravenous methylprednisolone 
without oral taper was allowed for MS relapse. 
Physical therapy was permitted, but an in-patient 
intensive physical therapy programme was not 
allowed in the 3 months prior to inclusion or during 
the trial because this could interfere with disability 
evaluation.
Outcomes
Neurological assessments were conducted by an 
examining neurologist every 12 weeks in the placebo-
controlled phase. All evaluation scales used in the 
study are described in detail in the supplementary 
materials, and Figure S1 shows the timing of study 
assessments.
The primary endpoint was the proportion of patients 
with improvement of MS-related disability at month 
9, confirmed at month 12. Improvement was defined 
as a decrease of ⩾0.5 point or ⩾1 point in EDSS (if 
baseline score was 6–7 or 4.5–5.5, respectively) or a 
⩾20% decrease in timed 25-foot walk (TW25) time, 
compared with the best EDSS or TW25 value recorded 
at either the screening or the randomisation visit. 
Since the TW25 was performed twice per visit, the 
baseline value was the best out of four values obtained 
at screening or randomisation. EDSS was assessed 
using the Neurostatus EDSS (www.neurostatus.net) 
by EDSS raters qualified to Neurostatus level C. In 
line with Multiple Sclerosis Functional Composite 
guidelines, TW25 times were truncated to 180 sec-
onds for times above 180 seconds or when the patient 
could not perform the test because of MS-related dis-
ability. The best of the two TW25 values achieved at 
each visit was recorded.
Secondary endpoints comprised mean change in 
EDSS from randomisation to month 12; mean clinical 
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global impression of change scored by the clinician 
(clinician-assessed Clinical Global Impression Scale 
(CGI)) and patient (subject-assessed Clinical Global 
Impression Scale (SGI)) at month 12; and mean 
changes from randomisation in the 12-item Multiple 
Sclerosis Walking Scale (MSWS), Short Form 36 
Health Survey (SF-36) subscores, TW25, modified 
Fatigue Impact Scale (MFIS), nine-hole peg test 
(9-HPT) and Kurtzke EDSS functional subscores. The 
proportion of patients with improvement of EDSS and 
TW25 values, stable EDSS or EDSS progression 
(⩾0.5 point or ⩾1 point if value at randomisation was 
4.5–5.5) at month 9 (confirmed at month 12) was also 
assessed. Safety was investigated by comparing the 
incidence of adverse events (AEs) and laboratory or 
electrocardiogram (ECG) findings between study 
arms. Magnetic resonance imaging (MRI) investiga-
tions (3DT1, T2-spin–echo, T2-fluid attenuated inver-
sion recovery (FLAIR) and post-gadolinium T1 
sequences) were conducted in 74 patients from six 
centres who are participating in a long-term ancillary 
study using non-conventional MRI sequences.
Statistical analysis
No controlled data for clinical outcomes with 
MD1003 were available at the time of study design 
for sample size calculation. Data from seven MS 
patients treated with MD1003 for >3 months were 
used to estimate that >40% of MD1003-treated 
patients might show a reduction in disability. While 
progressive MS patients typically do not exhibit a 
confirmed decrease in EDSS scores,13 and as a con-
servative approach, it was estimated that 10% of the 
placebo-treated patients might improve. It was esti-
mated that at least 105 patients (70 in the MD1003 
arm and 35 in the placebo arm) would be required to 
detect a difference in the proportion of patients dem-
onstrating clinical improvement with 90% power at a 
5% two-sided significance level.
Differences in proportions were compared between 
arms with Fisher’s exact test and differences in means 
with the non-parametric Mann–Whitney U test. All 
statistical analyses were two-sided and conducted on 
an intention-to-treat (ITT) basis with a significance 
level of 5% using SAS software (version 9.2). The 
primary endpoint was also analysed in patients who 
had assessments of EDSS or TW25 at screening, 
baseline, month 9 and month 12 without major proto-
col deviations (per-protocol population). The homo-
geneity of treatment effect for the primary endpoint 
was assessed in subgroup analyses stratified accord-
ing to fampridine treatment, baseline EDSS value 
(4.5–5.5 or 6–7) and treatment centre.
No imputation method was used to handle missing 
data for the primary endpoint as this could have over-
estimated the number of responding patients. The 
‘last observation carried forward’ approach was used 
to handle missing data for all supportive analyses, 
except for the EDSS change, EDSS progression and 
TW25 change where no imputation was used.
Results
Between October 2013 and January 2014, 166 patients 
were screened and 154 were randomised to MD1003 
(n = 103) or placebo (n = 51; Figure 1). All randomised 
patients received their intended treatment and were 
included in the ITT and safety populations. Baseline 
demographic characteristics were balanced between 
arms (Table 1), except for a non-significantly greater 
proportion of patients with PPMS in the MD1003 
arm. Approximately half of the patients (73/154) were 
receiving fampridine and 40% (62/154) had concomi-
tant DMTs. A similar proportion of patients in the 
MD1003 (19 (18.4%)) and placebo (10 (19.6%)) arms 
were on a physical therapy programme at baseline.
During the placebo-controlled phase, 12 (11.7%) 
MD1003-treated patients discontinued treatment 
(Figure 1) including six patients withdrawn due to 
AEs (suicide, mucocutaneous rash, asthenia, muscle 
spasms, abdominal pain and libido disorder). Nine 
(17.6%) placebo-treated patients discontinued treat-
ment including seven due to AEs (overdose, dry 
mouth, intracranial haemorrhage, mental disorder, 
extrasystoles, muscle spasticity and pregnancy). 
During the extension phase, 17 of the 91 (18.6%) 
patients in the MD1003 > MD1003 arm discontinued 
treatment (2 due to AEs: weight loss and breast can-
cer) as did 4 of the 42 (9.5%) patients in the pla-
cebo > MD1003 arm (1 due to AE: myopathy).
Primary endpoint
A total of 13 (12.6%; 95% confidence interval (CI): 
6.9%–20.6%) patients treated with MD1003 had a 
reduction in MS-related disability at month 9, con-
firmed at month 12, compared with none in the pla-
cebo arm (Figure 2; p = 0.005; effect estimate for 
difference in proportions: 0.13; asymptotic 95% CI: 
0.06–0.19). A total of 10 of the 13 (76.9%) patients 
with reduced disability had 3-month confirmed 
improved EDSS scores and 5 (38.5%) had improved 
TW25 times, while 2 (15.4%) improved on both 
scores. Baseline characteristics of the 13 responding 
patients are shown in Table 2. Results were similar in 
the per-protocol population (n = 129): 13 of the 87 
(14.9%) MD1003-treated patients achieved the 
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primary endpoint compared with none in the placebo 
arm (n = 42; p = 0.009). Pre-planned subgroup analy-
ses showed that the primary endpoint was reached 
more frequently in MD1003-treated patients not 
taking fampridine (12 of 58; 20.3%) than those taking 
fampridine (1 of 45; 2.3%) and in patients with base-
line EDSS 4.5–5.5 (6 of 28; 21.4%) versus EDSS 6–7 
(7 of 75; 9.3%; Table S1). Study centre, physical therapy 
Figure 1. Screening, enrolment, randomisation and follow-up of study patients. The ITT population was defined as 
all patients who were assigned to a treatment arm. The per-protocol population was defined as all patients of the ITT 
population with assessments of EDSS or TW25 at screening, baseline, month 9 and month 12 without major protocol 
deviations.
EDSS: Expanded Disability Status Scale; ITT: intention to treat; TW25: timed 25-foot walk.
A Tourbah, C Lebrun-Frenay et al.
http://msj.sagepub.com 1723
and disease history did not influence the proportion of 
patients achieving the primary endpoint.
A total of 12 of the 91 (13.2%; 95% CI: 7.0%–21.9%) 
patients initially treated with MD1003 had reduced 
MS-related disability at 18 months (confirmed at 
24 months; Figure 2), including 10 of the 13 (77%) 
patients who responded during the placebo-con-
trolled phase. After switching to MD1003, 3 of the 42 
(7.1%; 95% CI: 1.5%–19.5%) patients in the pla-
cebo > MD1003 arm had reduced disability at 
18 months (confirmed at 24 months). At month 24, 14 
of the 91 (15.4%) patients in the MD1003 > MD1003 
arm and 5 of the 42 (11.9%) patients in the pla-
cebo > MD1003 arm had reduced MS-related 
disability.
Secondary endpoints
Table 3 shows the results of secondary endpoints. The 
proportion of patients with EDSS progression at 
month 9 (confirmed at month 12) was 13.6% in the 
placebo arm and 4.2% in the MD1003 arm (p = 0.07). 
At month 18 (confirmed at month 24), the proportion 
increased to 31.7% in the placebo > MD1003 arm and 
9.9% in the MD1003 > MD1003 arm (p = 0.005).
At month 12, the mean (±standard deviation (SD)) 
EDSS decreased from baseline in the MD1003 arm 
(−0.03 ± 0.50) but increased at the expected rate in the 
placebo arm (+0.13 ± 0.33, p = 0.01; Figure 3). EDSS 
progression stopped after placebo patients were 
switched to MD1003, and mean EDSS values 
remained relatively constant to month 24 (+0.15 ± 0.37). 
Table 1. Baseline demographic characteristics of the intention-to-treat population.
MD1003 (n = 103) Placebo (n = 51)
Female sex, n (%) 53 (51.5) 30 (58.8)
Age, mean (SD) (years) 51.8 (9.1) 50.7 (8.4)
Disease phenotype, n (%)
 PPMS 42 (40.8) 13 (25.5)
 SPMS 61 (59.2) 38 (74.5)
Duration of MS, mean (SD) (years) 14.8 (8.9) 17.4 (10.3)
EDSS
 Mean (SD) 5.98 (0.75) 6.20 (0.52)
 Median (range) 6.0 (4.5–7.0) 6.0 (5.0–7.0)
 EDSS 4.5–5.5, n (%) 28 (27.2) 7 (13.7)
 EDSS 6–7, n (%) 75 (72.8) 44 (86.2)
TW25 (seconds)  
 Mean (SD) 21.8 (27.0) 30.6 (39.4)
 Median (range) 13.0 (4.0–180.0) 14.5 (4.8–180.0)
Physical therapy programme in the 3 months prior to 
inclusion, n (%)
19 (18.4) 10 (19.6)
Concomitant DMT, n (%) 42 (40.8) 20 (39.2)
 Mycophenolate mofetil 8 (7.8) 5 (9.8)
 Natalizumab 7 (6.8) 1 (2.0)
 Azathioprine sodium 4 (3.9) 1 (2.0)
 Fingolimod hydrochloride 2 (1.9) 2 (3.9)
 Cyclophosphamide monohydrate 6 (5.8) 3 (5.9)
 Cyclophosphamide 5 (4.9) 1 (2.0)
 Interferon beta-1a 4 (3.9)    0
 Interferon beta-1b 2 (1.9) 1 (2.0)
 Glatiramer acetate 2 (1.9) 1 (2.0)
 Methylprednisolone sodium succinate 16 (15.5) 15 (29.4)
 Methotrexate 2 (1.9) 4 (7.8)
Treatment with fampridine or amifampridine, n (%) 45 (43.7) 28 (54.9)
Treatment with muscle relaxants, n (%) 58 (56.3) 29 (56.9)
DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; PPMS: primary progressive 
multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis; TW25: timed 25-foot walk.
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In patients who remained on MD1003, mean EDSS 
was relatively stable over 24 months (+0.04 ± 0.62).
Mean TW25 times increased more in the placebo arm 
than in the MD1003 arm, but this difference was not 
significant (Table 3). The median TW25 time 
remained relatively constant in MD1003-treated 
patients throughout the study (Figure S3). Other post 
hoc analyses showed that in the MD1003 group, nine 
(8.7%) patients had >20% improvement in TW25 
times at month 9, confirmed at month 12, compared 
with the last pre-treatment visit versus none in the pla-
cebo group (p = 0.03). Furthermore, the proportion of 
patients unable to successfully perform the TW25 
Figure 2. Proportion of patients with reversal of MS-related disability. Reversal of disability was defined as 
improvement of EDSS or TW25 values confirmed at the next visit (except for month 24 where no subsequent visit was 
available) compared with best respective values recorded at either the screening or the randomisation visits.
EDSS: Expanded Disability Status Scale; TW25: timed 25-foot walk.
Table 2. Baseline characteristics of the 13 patients who achieved the primary endpoint of the study.
Age 
(years)
 
Sex (F/M) Centre PPMS or 
SPMS
MS duration 
(years)
Baseline 
EDSS
Improvement DMT
EDSS TW25  
68 M 1 PPMS 3.0 6.5 + –  
50 M 1 SPMS 14.0 6.5 – +  
52 M 2 PPMS 6.0 6.5 + – MPM
63 F 3 SPMS 12.0 4.5 + – INF
55 M 6 SPMS 18.0 7 – +  
43 M 6 SPMS 10.0 5.5 + + CP
52 F 9 SPMS 16.0 6.5 + – MPM
59 M 11 SPMS 12.0 7 + – MPM
62 M 11 PPMS 37.0 4.5 + – MTX
43 M 14 PPMS 5.0 4.5 + –  
64 M 14 SPMS 31.0 6.5 + +  
46 F 15 SPMS 15.0 4.5 + – INF
46 M 16 SPMS 25.0 5.5 – +  
Mean 54.0 23.1% F – 69.2% SPMS Mean 15.7 Mean 5.81 76.9% 38.5% 53.8%
CP: cyclophosphamide; DMT: disease-modifying therapy; F: female; EDSS: Expanded Disability Status Scale; INF: interferon; M: 
male; MPM: mycophenolate mofetil; MS: multiple sclerosis; MTX: methotrexate; PPMS: primary progressive multiple sclerosis; 
SPMS: secondary progressive multiple sclerosis; TW25: timed 25-foot walk.
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(values truncated at 180 seconds) progressed at a 
lower rate in the MD1003 group (from 1.0% at month 
0 to 6.4% at month 12), than in the placebo group 
(from 2.0% at month 0 to 19.0% at month 12; p = 0.07).
MD1003-treated patients had significantly lower CGI 
scores (mean = 4.05 ± 0.81 vs 4.62 ± 0.75; p < 0.001) 
and SGI scores (mean = 4.27 ± 1.05 vs 4.76 ± 0.89; 
p = 0.009) at month 12 compared with placebo-treated 
patients. There was no longer a difference between 
arms at month 24, driven by improvement in the pla-
cebo arm after switching to MD1003 (Table 3). 
Results of the MSWS assessments showed a non-sig-
nificant trend favouring MD1003. In contrast, SF-36 
subscores did not show consistent results favouring 
either treatment group.
Figure 3. Mean change from baseline in EDSS during the 12-month double-blind placebo-controlled phase and 
12-month extension phase. This figure also shows the mean change from baseline in EDSS (represented as the mean of 
means) as reported in other published placebo-controlled studies of pharmacological agents in PPMS or SPMS (>6000 
patients in total).7,9,14–22
EDSS: Expanded Disability Status Scale; DR 2/4 (+ or −): human leukocyte antigen haplotype (positive or negative); GA: glatiramer 
acetate; IFNb: interferon beta; PPMS: primary progressive multiple sclerosis; SEM: standard error of the mean; SPMS: secondary 
progressive multiple sclerosis; TW25: timed 25-foot walk.
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Safety
The incidence and distribution of AEs during the pla-
cebo-controlled phase were similar between arms 
(Table 4 and Table S2). Most reported AEs were mild 
or moderate. The only serious AE reported in more 
than one patient was MS relapse (five (4.9%) 
MD1003-treated patients and four (7.8%) placebo-
treated patients). One serious AE was reported to be 
possibly related to MD1003 (mucocutaneous rash), 
although subsequent chamber patch testing was nega-
tive for biotin. One death by suicide occurred during 
the study in the MD1003 arm and was not considered 
treatment related. AEs reported during the extension 
phase included MS relapses in 7 of the 91 (7.7%) 
patients who initially received MD1003 and in 2 of 
the 42 (4.8%) patients who initially received placebo. 
A total of two neoplasms not considered treatment 
related were found in two patients initially receiving 
MD1003.
Six cases of apparent hyperthyroidism (low thyroid-
stimulating hormone (TSH) and high triiodothyronine 
or thyroxine) were recorded as AEs in the MD1003 
arm during the placebo-controlled phase and in five 
additional patients during the extension phase (includ-
ing one patient who initially received placebo). This 
was determined to be due to biotin interference with 
the thyroid function laboratory tests that used a bioti-
nylated antibody.23 Only one of the six patients with 
apparent biological hyperthyroidism during the dou-
ble-blind phase was confirmed to have Basedow’s 
disease based on histological examination after 
thyroidectomy.
At month 12, MRI examination identified new 
MS-specific lesions in 11 of the 47 (23.4%) MD1003-
treated patients and 3 of the 23 (13.0%) placebo-
treated patients (p = 0.36). Four (8.5%) 
MD1003-treated patients had enlarging lesions (vs 
none in the placebo arm; p = 0.30) and two (4.3%) had 
at least one post-gadolinium enhancing lesion on T1 
sequence (vs none in the placebo arm; p = 0.99). Five 
patients had new T2 lesions during the extension 
phase, including one in the initial placebo arm (5.6%) 
and four in the initial MD1003 arm (10%).
Discussion
The primary endpoint of most trials in progressive 
MS is disability progression. As MD1003 is believed 
to target the nervous system, and not the immune sys-
tem, MS-SPI was instead designed and powered with 
disability improvement as the primary criterion. 
Results show that MD1003 can reverse MS-related 
disability in 12.6% of the patients, while this was 
observed in none of the placebo patients (p = 0.005). 
Treatment efficacy was maintained over 24 months in 
patients in the active treatment arm with 10 of the 13 
(77%) patients who responded initially showing sus-
tained improvement to month 24. Two additional 
patients in the active arm who did not show confirmed 
improvement in the first 12 months showed confirmed 
improvement at 24 months.
MD1003 also reduced the proportion of patients with 
confirmed EDSS progression. As a result of both dis-
ability improvement and decreased progression, the 
mean EDSS in the active treatment arm was almost 
unchanged over 24 months compared with baseline. 
Importantly, the mean EDSS increase observed under 
placebo was halted after patients were switched to 
MD1003 during the extension phase, with reversal of 
MS-related disability observed in some patients. 
However, the higher level of disability reached by 
these patients compared with those in the active treat-
ment arm suggests that delaying treatment initiation 
could lead to a loss of chance. This observation would 
favour a DMT effect of MD1003 rather than a simple 
symptomatic effect. On the other hand, the early 
improvement already observed after 3 months would 
favour a symptomatic effect. This early response was 
also observed in the placebo group (not confirmed at 
subsequent visits), which could also indicate an initial 
placebo effect.
EDSS progression observed in the placebo arm of 
MS-SPI was consistent with previous placebo data in 
progressive MS trials (Figure 3).7,9,14–22 The effect of 
MD1003 on EDSS change is strikingly different from 
observations in published placebo-controlled studies 
in progressive MS (Figure 3)7,9,14–22 which showed 
that mean EDSS scores under both active drug and 
placebo increased over the treatment period, irrespec-
tive of the differences in design and treatment 
interventions.
The improvements in CGI and SGI scores with 
MD1003 compared with placebo support the clinical 
meaningfulness of the results observed on EDSS. The 
low responsiveness of the TW25 endpoint was sur-
prising, as this parameter is usually sensitive to 
change.24 Other post hoc analyses support a superior-
ity of MD1003 over placebo on the TW25 measure 
which is consistent with results seen for EDSS.
MD1003 was well tolerated over 24-month treatment, 
consistent with data from the pilot study.11 The sui-
cide in the MD1003 arm was judged not to be treat-
ment related. This individual had severe and 
progressing MS and a past history of anxiety disorder 
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Table 4. Adverse events reported during the study.
12-month double-blind, placebo-controlled phase MD1003 (n = 103) Placebo (n = 51)
Any AE, n (%) 84 (81.6) 43 (84.3)
 AEs occurring in >2% of MD1003-treated patients
  Urinary tract infection 10 (9.7) 6 (11.8)
  Bronchitis 5 (4.9) 6 (11.8)
  Nasopharyngitis 5 (4.9) 3 (5.9)
  Multiple sclerosis relapse 5 (4.9) 4 (7.8)
  Hyperthyroidisma 6 (5.8) –
  Gastroenteritis 4 (3.9) 2 (3.9)
  Constipation 4 (3.9) 2 (3.9)
  Back pain 4 (3.9) 3 (5.9)
  Headache 4 (3.9) 3 (5.9)
  Muscle spasticity 4 (3.9) 6 (11.8)
  Nausea 3 (2.9) 2 (3.9)
  Oedema peripheral 3 (2.9) 1 (2.0)
  Cystitis 3 (2.9) 1 (2.0)
  Fall 3 (2.9) 2 (3.9)
  Dizziness 3 (2.9) 2 (3.9)
  Oropharyngeal pain 3 (2.9) –
Any TRAE, n (%) 20 (19.4) 12 (23.5)
 TRAEs occurring in >2% of MD1003-treated patients
  Headache 3 (2.9) –
Any severe AE,b n (%) 5 (4.9) 4 (7.8)
Any SAE,c n (%) 20 (19.4) 12 (23.5)
 SAEs occurring in more than one patient
  Multiple sclerosis relapse 5 (4.9) 4 (7.8)
12-month extension phase MD1003 > MD1003 (n = 91) Placebo > MD1003 (n = 42)
Any AE, n (%) 49 (53.8) 25 (59.5)
 AEs occurring in >2% of MD1003 > MD1003 patients
  Urinary tract infection 8 (8.8) 6 (14.3)
  Multiple sclerosis relapse 7 (7.7) 2 (4.8)
  Bronchitis 3 (3.3) 2 (4.8)
  Hyperthyroidisma 3 (3.3) 1 (2.4)
  Fall 3 (3.3) 1 (2.4)
  Abdominal pain 3 (3.3) –
  Eczema 3 (3.3) –
  Hypercholesterolaemia 2 (2.2) 1 (2.4)
  Nasopharyngitis 2 (2.2) –
  Back pain 2 (2.2) –
  Headache 2 (2.2) –
  Oedema peripheral 2 (2.2) –
  Musculoskeletal pain 2 (2.2) –
Any TRAE, n (%) 7 (7.7) 5 (11.9)
 TRAEs occurring in >2% of MD1003 > MD1003 patients
  None – –
Any severe AE,b n (%) 6 (6.6) 2 (4.8)
Any SAE,c n (%) 14 (15.4) 6 (14.3)
 SAEs occurring in more than one patient
  Multiple sclerosis relapse 6 (6.6) 2 (4.8)
AE: adverse event; MS: multiple sclerosis; SAE: serious adverse event; TRAE: treatment-related adverse event.
a Six patients had apparent hyperthyroidism in the placebo-controlled phase and five patients during the extension phase. One patient in the placebo-con-
trolled phase was confirmed to have Basedow’s disease; the remaining AEs reported as hyperthyroidism were believed to be due to abnormal thyroid 
function tests due to interference with the biotin-based assay systems used. An additional case of suspected hyperthyroidism in the MD1003 > MD1003 
group was identified but not reported as an AE.
b Severe events during the placebo-controlled phase were isolated cases of urinary tract infection, humerus fracture, suicide, mucocutaneous rash and 
rosacea in the MD1003 arm and isolated cases of fatigue, intracranial haematoma, MS relapse and bipolar disorder in the placebo arm. Severe events 
during the extension phase were isolated cases of vertigo, hyperthyroidism, hypoglycaemia, rectal cancer, MS relapse, lung disorder and menopause in 
the MD1003 > MD1003 group (seven events in six patients) and isolated cases of thyroiditis and myopathy in the placebo > MD1003 group.
cAn adverse event resulting in death, hospitalisation, disability, congenital anomaly or was otherwise life threatening.
AE: adverse event; SAE: serious adverse event; TRAE: treatment-related adverse event.
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treated with an anxiolytic. Individuals with MS have 
a higher rate of suicide than the general population.25
More new or enlarging MRI lesions occurred in the 
MD1003 arm than in the placebo arm during the dou-
ble-blind phase. Future trials should include careful 
assessment of MRI activity to rule out an unwanted 
pro-inflammatory effect of biotin. There are no pub-
lished data on animal models concerning a potential 
pro-inflammatory effect of high-dose biotin. Of note, 
MRI was not used to assess efficacy because of the 
relatively short trial duration which was not powered 
to see an effect on brain volume.
One important safety observation from this study was 
that MD1003 interferes with biotin-based laboratory 
tests. This results in falsely low values with sandwich 
immunoassays and false elevations with competitive 
immunoassays.23 This may potentially affect a wide 
range of laboratory assays, particularly the thyroid 
panel. This finding led to the recommendation to use 
non-biotin-based laboratory assays in patients taking 
MD1003.
Our study has some methodological limitations. The 
relative short follow-up of the placebo-controlled 
phase did not allow us to fully assess the potential 
disease-modifying effect of high-dose biotin. The 
number of responding patients was lower than our ini-
tial expectations, possibly because of the very strin-
gent primary endpoint used in this study. The absence 
of separate examining and treating physicians could 
have theoretically perturbed the study blinding 
(although biotin has no recognisable flavour or AEs). 
Of note, the success of blinding was not specifically 
assessed in this study. There were also some potential 
imbalances between the two treatment groups at 
baseline.
In conclusion, our data suggest that targeting neuron 
or oligodendrocyte metabolism with high-dose biotin 
may represent an effective and safe treatment for 
patients with progressive MS.
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